Literature DB >> 20129298

Atrial electrophysiological and structural remodeling in high-risk patients with Brugada syndrome: assessment with electrophysiology and echocardiography.

Norihisa Toh1, Hiroshi Morita, Satoshi Nagase, Manabu Taniguchi, Daiji Miura, Nobuhiro Nishii, Kazufumi Nakamura, Tohru Ohe, Kengo F Kusano, Hiroshi Ito.   

Abstract

BACKGROUND: Atrial fibrillation (AF) often occurs in Brugada syndrome (BrS), and BrS patients with spontaneous AF often experience ventricular fibrillation (VF) attacks. Atrial vulnerability providing a substrate for AF is known to be enhanced in BrS, but there are no data on atrial structural attributes.
OBJECTIVE: The objective of this study was to assess atrial electrophysiological and structural characteristics in BrS and their relationships with gene mutations.
METHODS: We studied 57 patients with BrS. Intra-atrial conduction time (CT) was defined as the interval from the stimulus at the high right atrium to atrial deflection at the distal portion of the coronary sinus. Left atrial volume index (LAVI) was measured by the modified Simpson method at left ventricular end-systole using echocardiography. SCN5A mutations were analyzed in all patients.
RESULTS: In patients with documented VF, spontaneous AF frequently occurred and prolonged CT and increased LAVI were observed compared with those in patients without VF (all P < .05; LAVI: 22 +/- 5 vs. 32 +/- 7 ml/m(2)). Even among patients without AF, CT and LAVI were still increased in patients with VF (all P < .05; LAVI: 22 +/- 5 vs. 29 +/- 5 ml/m(2)). The presence of SCN5A mutation was associated with prolonged CT (P < .05) and increased LAVI (P < .01), but not with arrhythmic episodes.
CONCLUSION: Both atrial vulnerability and structural remodeling are enhanced in high-risk patients with BrS, even in those without AF. These morphological characteristics suggest that BrS is a form of genetic myocardial disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20129298     DOI: 10.1016/j.hrthm.2009.10.035

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  7 in total

1.  Atrial arrhythmogenicity in aged Scn5a+/DeltaKPQ mice modeling long QT type 3 syndrome and its relationship to Na+ channel expression and cardiac conduction.

Authors:  Laila Guzadhur; Sarah M Pearcey; Rudolf M Duehmke; Kamalan Jeevaratnam; Anja F Hohmann; Yanmin Zhang; Andrew A Grace; Ming Lei; Christopher L-H Huang
Journal:  Pflugers Arch       Date:  2010-06-16       Impact factor: 3.657

2.  Updates on the inherited cardiac ion channelopathies: from cell to clinical.

Authors:  Jennifer N A Silva; Jonathan R Silva
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-10

3.  Scn2b Deletion in Mice Results in Ventricular and Atrial Arrhythmias.

Authors:  Yangyang Bao; B Cicero Willis; Chad R Frasier; Luis F Lopez-Santiago; Xianming Lin; Roberto Ramos-Mondragón; David S Auerbach; Chunling Chen; Zhenxun Wang; Justus Anumonwo; Héctor H Valdivia; Mario Delmar; José Jalife; Lori L Isom
Journal:  Circ Arrhythm Electrophysiol       Date:  2016-12

Review 4.  Atrial Fibrillation in Inherited Channelopathies.

Authors:  Baha'a Al-Azaam; Dawood Darbar
Journal:  Card Electrophysiol Clin       Date:  2021-01-08

Review 5.  Atrial arrhythmias in inherited arrhythmogenic disorders.

Authors:  Can Hasdemir
Journal:  J Arrhythm       Date:  2016-02-09

6.  Atrial electrical abnormality in patients with Brugada syndrome assessed by signal-averaged electrocardiography.

Authors:  Yasutsugu Nagamoto; Yuto Fujii; Yuichi Morita; Yusuke Ueda; Yasuko Miyake; Kenichi Yamane; Mai Fujiwara; Shinji Mito; Yuichiro Watari; Hiromichi Tamekiyo; Tomokazu Okimoto; Yuji Muraoka; Yasuhiko Hayashi
Journal:  Indian Heart J       Date:  2017-05-23

7.  Age-dependent electrical and morphological remodeling of the Drosophila heart caused by hERG/seizure mutations.

Authors:  Karen Ocorr; Alexander Zambon; Yoav Nudell; Santiago Pineda; Soda Diop; Min Tang; Takeshi Akasaka; Erika Taylor
Journal:  PLoS Genet       Date:  2017-05-19       Impact factor: 5.917

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.